title: Iron status and the treatment of the anemia of prematurity.
abstract: Many unanswered issues regarding rhEPO therapy in prematurity remain, including which premature infants best respond to rhEPO, what the long-term effect of decreased erythrocyte transfusions is, how nutritional supplementation optimizes the effect of rhEPO, whether or not rhEpo therapy causes iron deficiency later in life, and whether or not it is safe to supplement with parenteral iron. Further study of rhEPO therapy and iron status in prematurity is necessary.
authors.affiliation: Department of Pediatrics, Steele Memorial Children's Research Center, 1501 N. Campbell Ave., PO # 24-5073, The University of Arizona, Tucson, AZ 85724-5073, USA. pkling@facstaff.wisc.edu
authors.forename: Pamela J
authors.initials: PJ
authors.lastname: Kling
authors.forename: Joy J
authors.initials: JJ
authors.lastname: Winzerling
mesh_terms: D000740:Anemia / Q000378:metabolism / Q000628:therapy*; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000378:metabolism / Q000628:therapy*; D007501:Iron / Q000008:administration & dosage / Q000378:metabolism; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron